Health Care [ 4/12 ] | Biotechnology [ 7/75 ]
NASDAQ | Common Stock
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally.
The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine.
The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 26 | 0.11 Increased by +121.15% | -0.42 Increased by +126.15% |
| Nov 6, 25 | -1.25 Decreased by -64.93% | -0.54 Decreased by -130.33% |
| Aug 6, 25 | 0.62 Decreased by -37.37% | -0.06 Increased by +1.13 K% |
| May 8, 25 | 2.93 Increased by +379.05% | 0.71 Increased by +313.55% |
| Feb 26, 25 | -0.52 Increased by +63.89% | -0.51 Decreased by -1.21% |
| Nov 7, 24 | -0.76 Increased by +39.85% | -0.83 Increased by +8.69% |
| Aug 8, 24 | 0.99 Increased by +70.69% | 1.64 Decreased by -39.63% |
| May 10, 24 | -1.05 Increased by +69.21% | -1.06 Increased by +0.94% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 147.14 M Increased by +66.61% | 17.53 M Increased by +121.63% | Increased by +11.91% Increased by +112.98% |
| Sep 30, 25 | 70.44 M Decreased by -16.64% | -202.38 M Decreased by -66.84% | Decreased by -287.29% Decreased by -100.16% |
| Jun 30, 25 | 239.24 M Decreased by -42.42% | 106.51 M Decreased by -34.41% | Increased by +44.52% Increased by +13.91% |
| Mar 31, 25 | 666.65 M Increased by +610.30% | 518.65 M Increased by +451.51% | Increased by +77.80% Increased by +149.49% |
| Dec 31, 24 | 88.31 M Decreased by -69.69% | -81.03 M Increased by +54.58% | Decreased by -91.76% Decreased by -49.85% |
| Sep 30, 24 | 84.51 M Increased by +283.03% | -121.30 M Increased by +7.25% | Decreased by -143.53% Increased by +75.78% |
| Jun 30, 24 | 415.48 M Decreased by -2.11% | 162.38 M Increased by +179.93% | Increased by +39.08% Increased by +185.95% |
| Mar 31, 24 | 93.86 M Increased by +1.56 K% | -147.55 M Increased by +49.80% | Decreased by -157.21% Decreased by -103.44% |